Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IRIX
IRIX logo

IRIX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.220
Open
1.220
VWAP
1.05
Vol
434.54K
Mkt Cap
17.02M
Low
0.950
Amount
457.79K
EV/EBITDA(TTM)
--
Total Shares
17.19M
EV
21.15M
EV/OCF(TTM)
--
P/S(TTM)
0.33
IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Show More

Events Timeline

(ET)
2026-02-02
07:10:00
Iridex Relocates Headquarters to San Jose, Expects $400K Savings
select
2026-01-12 (ET)
2026-01-12
07:10:00
IRIDEX Expects Total Revenue of $14.6M to $14.8M in 2025
select
2025-12-11 (ET)
2025-12-11
07:20:00
Iridex Study Shows 25%-35% IOP Reduction in Glaucoma Patients Using MicroPulse Technology
select
2025-12-08 (ET)
2025-12-08
07:10:00
Iridex Publishes Study on Laser Treatments for Glaucoma
select
2025-09-09 (ET)
2025-09-09
16:41:28
Iridex Meets Nasdaq Listing Standards Again
select
2025-06-24 (ET)
2025-06-24
07:03:27
Iridex announces first patient enrolled in investigator-led study of MicroPulse
select
2025-03-19 (ET)
2025-03-19
09:20:49
Iridex appoints Romeo Dizon as CFO
select
2025-03-19
09:19:59
Iridex announces closing of strategic investment in company
select

News

seekingalpha
9.5
03-26seekingalpha
IRIDEX Corporation Q4 2025 Earnings Call Highlights
  • Significant Revenue Growth: IRIDEX reported total revenue of $14.7 million for Q4 2025, reflecting a 16% year-over-year increase, indicating sustained growth in core product lines, particularly in glaucoma and retina segments, which suggests strong market demand.
  • Cost Control Initiatives: The company plans to achieve quarterly savings of $165,000 starting Q1 2026 by relocating certain administrative functions out of California, and expects to reduce annual fixed costs by approximately $600,000 through a planned headquarters relocation, further enhancing profitability.
  • Strong Product Sales: In Q4, the glaucoma business sold 15,900 probes and 44 G6 systems, with total probe sales reaching 57,800 and system sales at 133 for the year, demonstrating the market acceptance and growth potential of the Cyclo G6 platform.
  • Optimistic Future Outlook: IRIDEX expects 2026 revenue to range from $51 million to $53 million, excluding contributions from the Middle East, indicating a growth potential of 1% to 5%, with management expressing confidence in future cash flows and margin improvements.
NASDAQ.COM
2.0
03-26NASDAQ.COM
IRIDEX (IRIX) Q4 2025 Earnings Call Transcript
seekingalpha
9.5
03-26seekingalpha
IRIDEX Q4 Earnings Beat Expectations Despite Revenue Miss
  • Earnings Performance: IRIDEX reported a Q4 GAAP EPS of -$0.01, beating expectations by $0.01, indicating a slight improvement in profitability despite missing revenue targets.
  • Revenue Growth: Total revenue for 2025 reached $52.7 million, an 8% increase from $48.7 million in 2024, reflecting a stable growth trend in the market, particularly driven by the glaucoma product line.
  • Product Sales: Revenue from the Cyclo G6® glaucoma product family was $13.8 million, up from $12.7 million in 2024, with sales of Cyclo G6® probes increasing from 55,400 to 57,800, demonstrating sustained demand for the products.
  • Cost Control: The company reduced operating expenses by 22% compared to the previous year, which not only enhances overall profitability but also provides greater financial flexibility for future investments and expansions.
moomoo
7.0
03-26moomoo
IRIDEX CORP: OUTLOOK REFLECTS EFFECTS OF MIDDLE EAST CONFLICT ON PRODUCT DELIVERY SCHEDULES DUE TO MARKET DISRUPTIONS
  • Market Disruptions: IrideX Corp. is assessing the impact of market disruptions caused by ongoing conflicts in the Middle East.

  • Product Delivery Challenges: The conflicts are affecting product delivery timelines, leading to potential delays and complications in supply chains.

moomoo
9.5
03-26moomoo
IRIDEX REPORTS Q4 GROSS PROFIT OF $5.5 MILLION
  • Financial Performance: IrideX reported a gross profit of $5.5 million for the fourth quarter.
  • Market Impact: The financial results indicate a positive trend in the company's performance, potentially influencing investor confidence.
Newsfilter
3.5
2025-12-11Newsfilter
Iridex's MicroPulse Technology Effectively Lowers Intraocular Pressure in Glaucoma Patients
  • Clinical Study Results: An independent study at the University Eye Clinic Maastricht shows that retreatment with MicroPulse laser treatment (MicroPulse TLT) reduces intraocular pressure (IOP) by 25% to 35% in glaucoma patients, demonstrating the technology's effectiveness and safety in glaucoma management.
  • Treatment Flexibility: The study involved 76 eyes, with retreatment timing varying from approximately 4 months to over 28 months, showcasing the individualized management capabilities of the technology, allowing for flexible treatment adjustments based on patient responses.
  • Success Rate of Repeat Treatments: Results indicate that patients who initially benefited from treatment have higher long-term success rates upon retreatment, aiding clinicians in better identifying candidates for retreatment and optimizing glaucoma management strategies.
  • Company Strategic Commitment: Iridex CEO Patrick Mercer stated that the findings further validate MicroPulse TLT as a valuable non-incisional option, reflecting the company's strong commitment to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.

Valuation Metrics

The current forward P/E ratio for IRIDEX Corp (IRIX.O) is -4.33, compared to its 5-year average forward P/E of -7.42. For a more detailed relative valuation and DCF analysis to assess IRIDEX Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.42
Current PE
-4.33
Overvalued PE
-3.09
Undervalued PE
-11.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.51
Current EV/EBITDA
-10.13
Overvalued EV/EBITDA
-3.27
Undervalued EV/EBITDA
-11.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.89
Current PS
0.39
Overvalued PS
1.46
Undervalued PS
0.32

Financials

AI Analysis
Annual
Quarterly

Whales Holding IRIX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IRIDEX Corp (IRIX) stock price today?

The current price of IRIX is 0.99 USD — it has decreased -26.67

What is IRIDEX Corp (IRIX)'s business?

IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.

What is the price predicton of IRIX Stock?

Wall Street analysts forecast IRIX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRIX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IRIDEX Corp (IRIX)'s revenue for the last quarter?

IRIDEX Corp revenue for the last quarter amounts to 12.48M USD, increased 7.80

What is IRIDEX Corp (IRIX)'s earnings per share (EPS) for the last quarter?

IRIDEX Corp. EPS for the last quarter amounts to -0.09 USD, decreased -25.00

How many employees does IRIDEX Corp (IRIX). have?

IRIDEX Corp (IRIX) has 93 emplpoyees as of March 31 2026.

What is IRIDEX Corp (IRIX) market cap?

Today IRIX has the market capitalization of 17.02M USD.